3rd Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

Firm
Client
Income
—
Expenses
$350,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

orphan drug tax credit; issues surrounding ADHD, including economic and social impact; binge eating disorder; drug shortages; DEA processes; FDA funding and sequester; specialty tiers; track and trace; bundling rules for the Hospital Outpatient Prospective Payment System; compassionate use; step therapy; line extension rebates; drug development; patent issues; CMS coding coverage; Medicare Part D rebates; tax reform; R&D tax credits; Priority Review Vouchers; FDASIA implementation

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —
JOHN EDWARD GREISSING —
MARK LENKER —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Office of Natl Drug Control Policy (NDCP); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.